"Mercaptopurine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
| Descriptor ID |
D015122
|
| MeSH Number(s) |
D02.886.489.534 D03.633.100.759.534
|
| Concept/Terms |
Mercaptopurine- Mercaptopurine
- 6-Thiopurine
- 6 Thiopurine
- 6-Mercaptopurine Monohydrate
- 6 Mercaptopurine Monohydrate
- 1,7-Dihydro-6H-purine-6-thione
- 6-Thiohypoxanthine
- 6 Thiohypoxanthine
|
Below are MeSH descriptors whose meaning is more general than "Mercaptopurine".
Below are MeSH descriptors whose meaning is more specific than "Mercaptopurine".
This graph shows the total number of publications written about "Mercaptopurine" by people in this website by year, and whether "Mercaptopurine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 2 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 2 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mercaptopurine" by people in Profiles.
-
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. Cancer Discov. 2022 11 02; 12(11):2646-2665.
-
Oral Mercaptopurine Adherence in Pediatric Acute Lymphoblastic Leukemia: A Survey Study From the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. J Pediatr Hematol Oncol Nurs. 2023 Jan-Feb; 40(1):17-23.
-
Sinusoidal Obstruction Syndrome of the Liver Associated With 6-Mercaptopurine During Maintenance in a Child With T-cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2023 01 01; 45(1):e121-e123.
-
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598.
-
Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2020 05; 61(5):1246-1249.
-
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
-
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 05; 104(5):986-992.
-
Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. Pediatr Blood Cancer. 2019 04; 66(4):e27577.
-
Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018 05 31; 131(22):2466-2474.
-
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018 01 25; 553(7689):511-514.